- Home
- Publications
- Publication Search
- Publication Details
Title
Bcl-2 antagonists: a proof of concept for CLL therapy
Authors
Keywords
Natural products, BH3 mimetics, Gossypol, CLL, Apoptosis
Journal
INVESTIGATIONAL NEW DRUGS
Volume 31, Issue 5, Pages 1384-1394
Publisher
Springer Nature
Online
2013-08-01
DOI
10.1007/s10637-013-0002-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
- (2013) Andrew J Souers et al. NATURE MEDICINE
- Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process
- (2012) M. Rahmani et al. BLOOD
- Experience with obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist in patients with relapsed or refractory classical Hodgkin lymphoma
- (2012) Y. Oki et al. BLOOD
- Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer
- (2012) C. M. Rudin et al. CLINICAL CANCER RESEARCH
- Discovery of Marinopyrrole A (Maritoclax) as a Selective Mcl-1 Antagonist that Overcomes ABT-737 Resistance by Binding to and Targeting Mcl-1 for Proteasomal Degradation
- (2012) Kenichiro Doi et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Bax and Bak are required for apogossypolone, a BH3-mimetic, induced apoptosis in chronic lymphocytic leukemia cells
- (2012) Kumudha Balakrishnan et al. LEUKEMIA & LYMPHOMA
- ABT-737 is highly effective against molecular subgroups of multiple myeloma
- (2011) L. Bodet et al. BLOOD
- Decreased sensitivity of 17p-deleted chronic lymphocytic leukemia cells to a small molecule BCL-2 antagonist ABT-737
- (2011) Kensuke Kojima et al. CANCER
- Mcl-1 and YY1 inhibition and induction of DR5 by the BH3-mimetic Obatoclax (GX15-070) contribute in the sensitization of B-NHL cells to TRAIL apoptosis
- (2011) Melisa A. Martínez-Paniagua et al. CELL CYCLE
- Tipping the Noxa/Mcl-1 Balance Overcomes ABT-737 Resistance in Chronic Lymphocytic Leukemia
- (2011) J. M. Tromp et al. CLINICAL CANCER RESEARCH
- ABT-737 Induces Apoptosis in Mantle Cell Lymphoma Cells with a Bcl-2high/Mcl-1lowProfile and Synergizes with Other Antineoplastic Agents
- (2011) Cyrille Touzeau et al. CLINICAL CANCER RESEARCH
- Proapoptotic Protein Smac Mediates Apoptosis in Cisplatin-resistant Ovarian Cancer Cells When Treated with the Anti-tumor Agent AT101
- (2011) Wenbin Hu et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Enhanced delivery of mda-7/IL-24 using a serotype chimeric adenovirus (Ad.5/3) in combination with the apogossypol derivative BI-97C1 (Sabutoclax) improves therapeutic efficacy in low CAR colorectal cancer cells
- (2011) Belal Azab et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors
- (2011) Leena Gandhi et al. JOURNAL OF CLINICAL ONCOLOGY
- Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease
- (2011) Andrew W. Roberts et al. JOURNAL OF CLINICAL ONCOLOGY
- Double-Blind, Placebo-Controlled, Randomized Phase 2 Study of the Proapoptotic Agent AT-101 Plus Docetaxel, in Second-Line Non-small Cell Lung Cancer
- (2011) Neal Ready et al. Journal of Thoracic Oncology
- A Phase II Study of AT-101 (Gossypol) in Chemotherapy-Sensitive Recurrent Extensive-Stage Small Cell Lung Cancer
- (2011) Maria Q. Baggstrom et al. Journal of Thoracic Oncology
- A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer
- (2011) Paul K. Paik et al. LUNG CANCER
- SCFFBW7 regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction
- (2011) Hiroyuki Inuzuka et al. NATURE
- Apogossypol derivative BI-97C1 (Sabutoclax) targeting Mcl-1 sensitizes prostate cancer cells to mda-7/IL-24-mediated toxicity
- (2011) R. Dash et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- ApoG2 inhibits antiapoptotic Bcl-2 family proteins and induces mitochondria-dependent apoptosis in human lymphoma U937 cells
- (2010) Jian Sun et al. ANTI-CANCER DRUGS
- The combination of a histone deacetylase inhibitor with the BH3-mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy
- (2010) Yue Wei et al. Autophagy
- Apogossypolone, a nonpeptidic small molecule inhibitor targeting Bcl-2 family proteins, effectively inhibits growth of diffuse large cell lymphoma cells in vitro and in vivo
- (2010) Yuan Sun et al. CANCER BIOLOGY & THERAPY
- Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo
- (2010) Clint Mitchell et al. CANCER BIOLOGY & THERAPY
- A natural BH3 mimetic induces autophagy in apoptosis-resistant prostate cancer via modulating Bcl-2–Beclin1 interaction at endoplasmic reticulum
- (2010) J Lian et al. CELL DEATH AND DIFFERENTIATION
- Diminished Sensitivity of Chronic Lymphocytic Leukemia Cells to ABT-737 and ABT-263 Due to Albumin Binding in Blood
- (2010) M. Vogler et al. CLINICAL CANCER RESEARCH
- The Bcl-2 Homology Domain 3 Mimetic Gossypol Induces Both Beclin 1-dependent and Beclin 1-independent Cytoprotective Autophagy in Cancer Cells
- (2010) Ping Gao et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Synthesis and Biological Evaluation of Apogossypolone Derivatives as Pan-active Inhibitors of Antiapoptotic B-Cell Lymphoma/Leukemia-2 (Bcl-2) Family Proteins
- (2010) Jun Wei et al. JOURNAL OF MEDICINAL CHEMISTRY
- BI-97C1, an Optically Pure Apogossypol Derivative as Pan-Active Inhibitor of Antiapoptotic B-Cell Lymphoma/Leukemia-2 (Bcl-2) Family Proteins
- (2010) Jun Wei et al. JOURNAL OF MEDICINAL CHEMISTRY
- Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
- (2010) Wyndham H Wilson et al. LANCET ONCOLOGY
- The MCL-1 BH3 helix is an exclusive MCL-1 inhibitor and apoptosis sensitizer
- (2010) Michelle L Stewart et al. Nature Chemical Biology
- Design and Synthesis of a Gossypol Derivative with Improved Antitumor Activities
- (2009) Yonghua Zhan et al. ARCHIV DER PHARMAZIE
- Different forms of cell death induced by putative BCL2 inhibitors
- (2009) M Vogler et al. CELL DEATH AND DIFFERENTIATION
- Apogossypol Derivatives as Pan-Active Inhibitors of Antiapoptotic B-Cell Lymphoma/Leukemia-2 (Bcl-2) Family Proteins
- (2009) Jun Wei et al. JOURNAL OF MEDICINAL CHEMISTRY
- ApoG2 induces cell cycle arrest of nasopharyngeal carcinoma cells by suppressing the c-Myc signaling pathway
- (2009) Zhe-Yu Hu et al. Journal of Translational Medicine
- The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia
- (2009) K D Mason et al. LEUKEMIA
- Bim Upregulation by Histone Deacetylase Inhibitors Mediates Interactions with the Bcl-2 Antagonist ABT-737: Evidence for Distinct Roles for Bcl-2, Bcl-xL, and Mcl-1
- (2009) S. Chen et al. MOLECULAR AND CELLULAR BIOLOGY
- Apogossypol derivatives as antagonists of antiapoptotic Bcl-2 family proteins
- (2009) J. Wei et al. MOLECULAR CANCER THERAPEUTICS
- BCL-2 Family Inhibitors Enhance Histone Deacetylase Inhibitor and Sorafenib Lethality via Autophagy and Overcome Blockade of the Extrinsic Pathway to Facilitate Killing
- (2009) A. P. Martin et al. MOLECULAR PHARMACOLOGY
- Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival
- (2009) Martin Schwickart et al. NATURE
- Bcl-2 antagonist apogossypol (NSC736630) displays single-agent activity in Bcl-2-transgenic mice and has superior efficacy with less toxicity compared with gossypol (NSC19048)
- (2008) S. Kitada et al. BLOOD
- Gossypol, a BH3 mimetic, induces apoptosis in chronic lymphocytic leukemia cells
- (2008) K. Balakrishnan et al. BLOOD
- Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia
- (2008) M. Vogler et al. BLOOD
- Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma
- (2008) L. Paoluzzi et al. BLOOD
- Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia
- (2008) S. M. O'Brien et al. BLOOD
- The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies
- (2008) L. Paoluzzi et al. BLOOD
- AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance
- (2008) K. Balakrishnan et al. BLOOD
- Gossypol suppresses NF-κB activity and NF-κB-related gene expression in human leukemia U937 cells
- (2008) Dong-Oh Moon et al. CANCER LETTERS
- Synthesis and evaluation of Apogossypol atropisomers as potential Bcl-xL antagonists
- (2008) Jun Wei et al. CANCER LETTERS
- Mechanisms of Antileukemic Activity of the Novel Bcl-2 Homology Domain-3 Mimetic GX15-070 (Obatoclax)
- (2008) M. Konopleva et al. CANCER RESEARCH
- ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
- (2008) C. Tse et al. CANCER RESEARCH
- A novel paradigm for rapid ABT-737-induced apoptosis involving outer mitochondrial membrane rupture in primary leukemia and lymphoma cells
- (2008) M Vogler et al. CELL DEATH AND DIFFERENTIATION
- A Phase I Study of the Pan Bcl-2 Family Inhibitor Obatoclax Mesylate in Patients with Advanced Hematologic Malignancies
- (2008) A. D. Schimmer et al. CLINICAL CANCER RESEARCH
- Activity of the Bcl-2 Family Inhibitor ABT-263 in a Panel of Small Cell Lung Cancer Xenograft Models
- (2008) A. R. Shoemaker et al. CLINICAL CANCER RESEARCH
- BH3 Mimetic Obatoclax Enhances TRAIL-Mediated Apoptosis in Human Pancreatic Cancer Cells
- (2008) S. Huang et al. CLINICAL CANCER RESEARCH
- A novel BH3 ligand that selectively targets Mcl-1 reveals that apoptosis can proceed without Mcl-1 degradation
- (2008) Erinna F. Lee et al. JOURNAL OF CELL BIOLOGY
- BCL-2 phosphorylation modulates sensitivity to the BH3 mimetic GX15-070 (Obatoclax) and reduces its synergistic interaction with bortezomib in chronic lymphocytic leukemia cells
- (2008) P Pérez-Galán et al. LEUKEMIA
- Preclinical studies of Apogossypolone: a new nonpeptidic pan small-molecule inhibitor of Bcl-2, Bcl-XL and Mcl-1 proteins in Follicular Small Cleaved Cell Lymphoma model
- (2008) Alan A Arnold et al. Molecular Cancer
- ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo
- (2008) Scott Ackler et al. MOLECULAR CANCER THERAPEUTICS
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started